Suzhou Highfine Biotech Co., Ltd. Class A

Suzhou Highfine Biotech Co., Ltd. Class A

SSZSE:301393
52.00
CNY
-1.00
(-1.89%)
1.10EPS
58.27P/E
7.25BMarket Cap
Apr 15Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.14
1.65
2.19
8.82
3.14
1.75
2.37
3.49
4.58
5.53
4.2
4.2
5.62
7.07
Basic EPS, GAAP
0.05
0.1
0.32
1.92
0.76
0.49
0.72
0.5
1.38
1.6
1.07
1.25
1.07
1.15
Free Cash Flow per Basic Share
-0.03
0.04
0.19
1.16
0.65
0.31
0.12
0.27
0.28
0.71
-0.35
0.17
-1.24
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
0.13
- -
- -
0.25
0.29
0.37
0.41
0.4
Book Value per Share
0.35
0.46
0.77
1.89
2.65
4.18
2.14
3.22
4.6
5.95
20.48
21
21.79
22.6
Tangible Book Value per Share
0.35
0.46
0.77
1.89
2.65
4.18
1.95
2.95
4.6
5.65
20.26
20.39
20.27
21.09
Basic Weighted Avg Shares
30
30
30
10
30
81
81
81
81
81
92
107
107
107
Sales/Revenue/Turnover
34
50
66
88
94
142
191
282
369
447
389
452
602
757
Operating Margin (%)
6.71
7.54
16.89
23.31
29.64
30.14
34.08
20.76
100
32.41
22.79
24.72
19.37
17.92
Depreciation Expense
1
1
1
1
1
1
2
2
18
12
14
20
38
- -
Net Income, GAAP
2
3
9
19
23
40
58
40
111
129
99
134
115
123
Effective Tax Rate (%)
23.6
14.3
15.08
15.5
14.72
13.34
13.92
26.03
13.68
13.15
12.01
13.31
14.25
15.02
Profit Margin (%)
4.61
6.34
14.42
21.77
24.2
27.99
30.39
14.31
30.15
28.91
25.46
29.67
19.04
16.29
Working Capital
7
8
18
52
74
119
153
149
205
243
1,898
1,873
1,451
1,350
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
1
- -
1
2
40
118
Total Equity
11
14
23
57
79
125
173
261
373
482
2,212
2,268
2,359
2,446
Return on Invested Capital (%)
- -
25.9
52.52
44.21
32.53
38.4
40.11
19.61
36.6
30.09
7.29
6.02
5.28
5.32
Return on Capital (%)
- -
25.81
51.26
48.01
33.44
38.77
38.89
18.56
35.04
30.24
7.34
5.98
5.09
5.13
Return on Common Equity (%)
- -
25.81
51.26
48.01
33.44
38.77
38.89
18.61
35.18
30.27
7.35
5.98
4.96
5.18

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
11
11
1
LT Borrowings
76
108
118
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
108
108
108
Market Capitalization
5,617
6,995
7,250

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,760
1,717
1,571
Cash, Cash Equivalents & STI
1,364
1,257
1,034
Accounts Receivable, Net
171
217
244
Inventories
166
166
188
Total Current Liabilities
325
350
221
Payables & Accruals
- -
- -
- -
ST Debt
11
11
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
76.81%
87.5%
4.01%
Free Cash Flow
-71.21%
-193.9%
-814.08%
Net Income, GAAP
40.07%
37.87%
-14.47%
Sales/Revenue/Turnover
26.24%
17.67%
33.28%
Total Cash Common Dividend
- -
41,880.25%
8.09%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
134
103
124
452
2025
135
135
- -
168
602
2026
172
207
211
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.34
0.29
0.35
1.25
2025
0.33
0.38
- -
0.14
1.07
2026
0.31
0.35
0.35
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.12
0.37
2025
- -
- -
- -
0.14
0.41
2026
- -
0.27
-0.01
- -
- -

Company Description

CEO
Yong Zhu
Full Time Employees
678
Sector
Process industries
Industry
Chemicals: major diversified
Address
Suzhou China
IPO Date
Jul 12, 2023
Business
Suzhou Highfine Biotech Co., Ltd. is a China-based biochemical synthesis and specialty chemical manufacturing company that develops, produces, and sells specialty reagents and advanced intermediates for the global pharmaceutical, biotechnology, and active pharmaceutical ingredient (API) industries. Founded in 2003 and headquartered in Suzhou, Jiangsu Province, China, the company operates across comprehensive chemical product segments and technical service offerings, including: peptide synthesis reagents, featuring uronium, phosphonium, and carbodiimide coupling reagents, condensation agents, racemization suppressants, and specialized protecting reagents; molecular building blocks and unnatural amino acids for medicinal chemistry and rational drug discovery; protein crosslinkers, chemical linkers, and functional payloads engineered for antibody-drug conjugates (ADCs); nucleotide synthesis reagents, phosphoramidites, and solid supports used in oligonucleotide therapeutics and mRNA technologies; proteolysis targeting chimera (PROTAC) building blocks and E3 ligase ligands; lipid excipients and lipid nanoparticle (LNP) reagents for targeted drug delivery platforms; ionic liquids and heterocyclic compounds; and custom development and manufacturing organization (CDMO) as well as contract research organization (CRO) services encompassing custom synthesis, chemical route scouting, process optimization, and commercial batch manufacturing. The company distributes its products to innovative pharmaceutical corporations, generic drug manufacturers, contract research organizations, and academic institutions across domestic China, North America, Europe, Japan, South Korea, and Southeast Asia. The company executes its manufacturing and research operations through key subsidiaries, including Anhui Highfine Biotech Co., Ltd., Huai'an Highfine Biotech Pharmaceutical Co., Ltd., and Hangzhou Foster Pharmaceutical Co., Ltd. In recent developments, the company listed its Class A shares on the ChiNext board of the Shenzhen Stock Exchange (SZSE:301393) to accelerate production and R&D infrastructure expansion. Suzhou Highfine Biotech completed the acquisition of an 85% equity stake in Hangzhou Foster Pharmaceutical Co., Ltd., integrating its GMP- and FDA-compliant production assets to broaden its regulated pharmaceutical manufacturing and fine chemical processing capabilities. Additionally, the company initiated construction on an approximately 1.8 billion RMB manufacturing base in Huai'an to deliver an annual capacity of 3,010 tons of peptide synthesis reagents, while also expanding its Anhui production base with 19 new product lines totaling 980 tons of specialized reagent capacity and commissioning its centralized corporate research and development headquarters in Suzhou.